Tucatinib
(Redirected from Tukysa)
What is Tucatinib?[edit | edit source]
- Tucatinib (Tukysa) is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
What are the uses of this medicine?[edit | edit source]
This medicine is used with the medicines trastuzumab and capecitabine to treat adults with:
- human epidermal growth factor receptor-2 (HER2) positive breast cancer that has spread to other parts of the body such as the brain (metastatic), or that cannot be removed by surgery, and
- who have received one or more anti-HER2 breast cancer treatments.
How does this medicine work?[edit | edit source]
- Tucatinib An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity.
- Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
- ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.
Who Should Not Use this medicine ?[edit | edit source]
- This medicine have no usage limitations.
What drug interactions can this medicine cause?[edit | edit source]
Avoid concomitant use with :
- strong CYP3A inducers or moderate CYP2C8 inducers.
- Strong CYP2C8 Inhibitors
- CYP3A Substrates
- P-gp Substrates
Is this medicine FDA approved?[edit | edit source]
- It was approved for use in the United States in 2020.
How should this medicine be used?[edit | edit source]
Recommended Dosage
- The recommended dosage of Tukysa is 300 mg taken orally twice daily in combination with trastuzumab and capecitabine until disease progression or unacceptable toxicity.
- For patients with severe hepatic impairment, the recommended dosage is 200 mg orally twice daily.
Administration
- Take Tukysa exactly as your healthcare provider tells you.
- Tukysa is used with the medicines trastuzumab and capecitabine. Your healthcare provider will tell you the dose of trastuzumab and capecitabine you will take and how you will receive them.
- Take Tukysa 2 times a day, with or without a meal.
- Take Tukysa about 12 hours apart or at the same times every day.
- Swallow Tukysa tablets whole. Do not chew, crush, or split Tukysa tablets before swallowing. Do not take Tukysa tablets if they are broken, cracked, or damaged.
- If you vomit or miss a dose of Tukysa, take your next dose at your regular time.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- As Tablets: 50 mg and 150 mg
This medicine is available in fallowing brand namesː
- Tukysa
What side effects can this medication cause?[edit | edit source]
Common possible side effects and laboratory abnormalities of this medicine include:
- diarrhea
- rash, redness, pain, swelling or blisters on the palms of your hands or soles of your feet
- nausea
- tiredness
- increased liver function blood tests
- vomiting
- mouth sores (stomatitis)
- decreased appetite
- stomach-area (abdomen) pain
- headache
- low red blood cell counts (anemia)
- rash
Tukysa may cause serious side effects, including:
- Diarrhea: Diarrhea is common with Tukysa and can sometimes be severe.
- Liver Problems: Tukysa can cause severe liver problems.
What special precautions should I follow?[edit | edit source]
- Severe diarrhea, including dehydration, acute kidney injury, and death, has been reported. Administer antidiarrheal treatment as clinically indicated. Interrupt dose, then dose reduce, or permanently discontinue Tukysa based on severity.
- Severe hepatotoxicity has been reported on Tukysa. Monitor ALT, AST and bilirubin prior to starting Tukysa, every 3 weeks during treatment and as clinically indicated. Interrupt dose, then dose reduce, or permanently discontinue Tukysa based on severity.
- Tukysa can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.
What to do in case of emergency/overdose?[edit | edit source]
- In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.
- Overdose related information is also available online at poisonhelp.org/help.
- In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
Can this medicine be used in pregnancy?[edit | edit source]
- Tukysa can cause fetal harm when administered to a pregnant woman.
- There are no available human data on Tukysa use in pregnant women to inform a drug-associated risk.
Can this medicine be used in children?[edit | edit source]
- The safety and effectiveness of Tukysa in pediatric patients have not been established.
What should I know about storage and disposal of this medication?[edit | edit source]
- Store at controlled room temperature, 20ºC to 25ºC (68ºF to 77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF) .
- Dispense to patient in original container only. Store in original container to protect from moisture.
- Replace cap securely each time after opening. Do not discard desiccant.
- Once opened, use within 3 months.
- Discard any unused tablets 3 months after opening the bottle.
Tucatinib Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Deepika vegiraju